IRVINE, Calif.–(BUSINESS WIRE)–Cloudbreak Pharma, a clinical stage biotechnology company developing ophthalmic drugs for common eye diseases with few treatment options, shared new data from a company-supported survey highlighting the patient burden of pterygium at the annual ASCRS meeting in Boston. Pterygium is an ocular disease commonly referred to as “surfer’s…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
